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Abstract A conjugate of the antineoplastic drug daunomyein 
(DNM) with maleylated bovine serum albumin (MBSA-DNM) 
was taken up with high efficiency by a multidrug resistant variant, 
JD100, of the murine-macrophage tumour cell line, J774A.1, 
through the scavenger eceptors resulting in cessation of DNA 
synthesis. In contrast, free DNM at similar concentrations did 
not affect the incorporation of [3H]thymidine by these cells. These 
results suggest hat receptor-mediated intracellular delivery of 
antineoplastic drugs could be a viable and new approach for 
overcoming the problem of multidrug resistance in chemotherapy 
of neoplastic diseases. 
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1. Introduction 
ously shown that cytotoxicity of daunomycin (DNM) against 
human histiocytic lymphoma U937 in vitro [13], and murine 
J774A. 1 tumour cells in vitro and in vivo [14,15], can be mark- 
edly enhanced by conjugation of the drug with maleylated bo- 
vine serum albumin (MBSA) which is recognized by scavenger 
receptors expressed primarily on cells of macrophage lineage 
[16-18]. To overcome the Pgp efflux pump and other putative 
permeability barriers, in the present study we have utilized the 
approach of scavenger-receptor mediated elivery of macro- 
molecular drug conjugates to multidrug resistant cells. We 
show that the DNM-conjugate of MBSA is recognised by scav- 
enger receptors and causes cessation of DNA synthesis in a 
DNM-resistant subline, JD100, derived from murine macro- 
phage tumour cell line J774A.1. To our knowledge, this is the 
first report demonstrating the efficacy of receptor-mediated 
drug delivery approach to restore DNM sensitivity in DNM- 
resistant cells exhibiting multidrug resistance. 
Resistance to a wide variety of structurally and functionally 
d~ssimilar cytotoxic drugs, termed multidrug resistance 
(MDR), is a major obstacle to success in chemotherapy of
h,aman cancers. MDR in human cancer appears to be multifac- 
t,,rial. In a large number of cancer cell lines and some human 
h ~matopoietic malignancies, MDR is associated with the over- 
p "oduction of a membrane protein, P-glycoprotein (Pgp). Pgp 
in an ATP-dependent pump of broad specificity which mediates 
etttux of many amphipathic lipophilic drugs, and thus prevents 
a~:cumulation f drug in sufficient concentration effective in 
h~tting the intracellular target sites (reviewed in [1,2]. Mecha- 
n Esms other than Pgp-mediated transport also appear to reduce 
i~Etracellular drug levels in cancer cells, for which sufficient 
nkolecular details are not yet available [3,4]. The mainstay of 
c arrent strategy for overcoming MDR in cancer chemotherapy 
i~ combination regimens with agents that block the action or 
e ~pression of Pgp [5-8]. However, alternative strategies to over- 
come multidrug resistance need to be developed since such 
1: iockade of Pgp function in normal cells could exert deleterious 
e~t'ects, and, additionally, all clinical manifestations of MDR 
a "e unlikely to be mediated by Pgp. 
Since Pgp mediates efflux of drugs in the plasma membrane, 
it is conceivable that this barrier can be circumvented by the 
u~e of liposome-encapsulated drugs [9 11] and receptor-medi- 
a :ed drug delivery systems (reviewed in [12]). We have previ- 
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2. Materials and methods 
2.1. Materials" 
Tissue culture supplies were from Grand Island Biological Co. 
(Grand Island, NY). Tissue culture media used were as follows: Me- 
dium A consisted of DMEM with 10% fetal calf serum (FCS), 2 mM 
L-glutamine, 0.37% sodium bicarbonate, and 50/zg/ml gentamycin; 
Medium B is medium A containing 100 ng/ml of DNM; Medium C is 
medium A without bicarbonate and FCS but containing 1mg/ml bo- 
vine serum albumin (BSA); Medium D is medium C with bicarbonate. 
DNM, BSA, polyguanylic acid, and verapamil were purchased from 
Sigma Chemical Co. (St. Louis, MO). [3H]Thymidine and NalZSl were 
purchased from Amersham International (Amersham, UK). Other ea- 
gents used were of analytical grade. 
2.2. Cells 
J774A.1, a mouse tumour cell line of monocyte-macrophage origin 
(American Type Culture Collection) was cultured in medium A at 37°C 
in a 5% CO2--95% air atmosphere. 
2.3. Development of drug resistant cells 
A drug-resistant subline of J774A. 1 cells was developed by continu- 
ous exposure of these cells to stepwise increasing concentrations of 
DNM from 25-100 ng/ml over the course of about a year as described 
[19]. These cells, named JD 100, were maintained inmedium A contain- 
ing 20% FCS in presence of DNM (100 ng/ml). The DNM-resistant 
phenotype expressed by these cells was stable for at least six months 
during the course of this study. 
2.4. Preparation of drug conjugate 
BSA was maleylated atpH 8.0 by using maleic anhydride as previ- 
ously described [14]. To prepare daunomycin drug conjugate, 3 mg of 
MBSA was mixed with 400/zg of DNM in 1 ml phosphate-buffered 
saline (PBS) followed by dropwise addition of glutaraldehyde (0.1%) 
to a final concentration f 0.01% of glutaraldehyde. The contents were 
stirred for 15 min at room temperature. The reaction was stopped by 
adding 50/tl of 1 M lysine followed by separation of drug conjugate 
from low molecular weight components by Sephadex G-50 gel filtra- 
tion. Void volume fractions containing the MBSA-DNM conjugate 
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were pooled and subjected to extensive dialysis against PBS. DNM 
content of the conjugate was determined by measuring the absorbance 
at 495 nm [20]. MBSA showed no absorbance at 495 nm. Protein was 
measured by using bicinchoninic acid (BCA) reagent [21]. The drug 
conjugate contained 3-4 moles of DNM per mole of MBSA. 
2.5. Radioiodination of MBSA DNM 
MBSA DNM conjugate was radioiodinated with Na~25I by the io- 
dine monochloride method as previously described [14,22]. More than 
99% of the radioactivity associated with the drug conjugate was trichlo- 
roacetic acid (TCA)-precipitable. The specific activity of the radiola- 
beled drug conjugate was approximately 120 cprrdng of protein. 
2.6. Binding of [12Sl]MBSA DNM by JD 100 and J774A.1 cells" 
at 4 ° C 
J774A. 1 and JD100 cells (5 x 105 cells) in 24-well tissue culture clus- 
ters were incubated in 1 ml of medium A or medium B, respectively, 
at 37°C. After 24 h, monolayers were washed twice with 1 ml of ice cold 
FCS free medium A. These cells were incubated at 4°C in 1 ml of 
medium C containing 6 pg/ml of[125I]MBSA-DNM in the presence and 
absence of competing compounds, i.e. MBSA (300pg/ml), polyguanylic 
acid (300 pg/ml), and DNM (5 pg/ml). After 2 h, cells were washed three 
times with ice-cold PBS containing 1mg/ml of BSA and once with PBS. 
The cells were dissolved in 1 ml of 0.1 N NaOH, and the amount of 
radioactivity associated with the cells was determined [14]. Cellular 
protein was estimated using an aliquot of the cell lysate by BCA method 
[21]. Results were expressed as ng of [125I]MBSA-DNM bound per mg 
of cellular protein. 
2. 7. Assay of uptake and degradation of [12Sl]MBSA-DNM 
JD100 and J774A.1 monolayer cells in 24-well tissue culture plates 
as described earlier were washed twice with 1 ml of FCS free medium 
A. To each well was added 1 ml of medium D containing 6¢tg/ml of 
[125I]MBSA DNM. Where indicated, the competing compounds, 
MBSA (300 pg/ml), polyguanylic acid (300,ug/ml), and DNM (5,ug/ml) 
were added to the wells and contents incubated at 37°C in 5% CO2-95% 
air atmosphere. After 5 h, the amount of TCA soluble (noniodide) 
radioactivity released in the medium was measured as described [14,22]. 
Monolayer cells were washed three times with ice cold PBS containing 
1 mg/ml of BSA and once with PBS. The cells were lysed in 1 ml of 0.1 
N NaOH and the cell-associated cellular adioactivity and protein con- 
tent were estimated as described above. Results were expressed as ng 
of [125I]MBSA-DNM degraded per mg of cellular protein. 
2.8. Cytotoxicity assay in vitro 
The cytotoxicity of the drug conjugate was assayed by the [SH]thy- 
midine uptake assay. J774A.I and JD100 monolayer (1 x l0 s cells) in 
24-well tissue culture clusters were washed twice with 1 ml of medium 
A and the cells were incubated in 1 ml of medium A containing indi- 
cated concentrations of DNM either in free or conjugated form, for 60 
min (Fig. 2), or indicated times (Fig. 3), at 37°C in an incubator 
containing 5% CO2. Subsequently, the cells were washed thrice with 
1 ml of medium A and incubated in 1 ml of drug free medium at 37°C. 
After 20 h the cells were incubated with 1 ml of medium A containing 
[3H]thymidine (2 pCi/ml) at 37°C for 3 h. The cells were then washed 
four times with 1 ml of medium A to remove the unincorporated 
radioactivity. Cells were then lysed in 0.5 ml of 0.1 N NaOH and the 
amount of radioactivity associated with the cells was determined. The 
results are expressed as percentage of[SH]thymidine incorporated ofthe 
control cells. 
3. Results and discussion 
A DNM-resistant subline, referred to as JD100, was gener- 
ated by stepwise exposure of murine macrophage J774A.1 
tumor cells to increasing concentrations of DNM as described 
in section 2. Table 1 shows the concentrations of different drugs 
required to cause 50% inhibition of [SH]thymidine incorpora- 
tion by the parental J774A. 1 and the drug-resistant JD 100 cells. 
JD100 cells were 15-fold more resistant o DNM compared to 
J774A.1 cells and also showed cross-resistance to doxorubicin 
(DXR, 32-fold), methotrexate (Mtx, 60-fold), vincristine (Vin, 
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Table l 
Inhibition of [SH]thymidine incorporation by J774A.1 and JDI00 cells 
by different drugs 
Drugs IC5o (pM) Fold resistance 
J774A.1 JD100 
Daunomycin 0.05 0.75 15 
Doxorubicin 0.025 0.81 32.4 
Methotrexate 0.5 30 60 
Vincristine 0.007 0.11 16 
5-Flurouracil 0.77 4.3 5.6 
Mitomycin C 0.3 1 3 
J774A. 1 and JD 100 cells ( 1 x 105) were treated with different concentra- 
tions of the indicated drugs for 20 h, and subsequently exposed to 
[3H]thymidine (2 pCi/ml) for 3 h as described in section 2. [SH]thymidine 
incorporation by untreated cells was taken as 100%. Concentration of
respective drugs required for 50% inhibition of [SH]thymidine incorpo- 
ration (IC50) by the respective cells are tabulated here and the results 
are expressed as the average of three independent determinations. 
16-fold), 5-flurouracil (5-Fu, 6-fold), and mitomycin C (Mit C, 
3-fold) suggesting that the JD100 cells had acquired the MDR 
phenotype. 
To further characterise the MDR phenotype in JD100 cells, 
we determined the cytotoxic activity of above mentioned rugs 
on JDI00 cells in the presence and absence o f20pM verapamil, 
an inhibitor of Pgp mediated drug efflux [23]. As shown in 
Table 2, DNM,  DXR, Vin, and Mit C exerted substantial 
cytotoxic effect on JD100 cells as measured by [3H]thymidine 
incorporation in the presence of 20/.tM verapamil, suggesting 
that resistance to these drugs in JD100 cells was mediated by 
Pgp. Drugs known to be insensitive to Pgp-mediated efflux, 
viz., Mtx and 5-Fu, did not show significant cytotoxic activity 
even in presence of verapamil. These data suggest that the 
MDR phenotype xpressed by the JD100 cells is of a complex 
nature resembling that often found in clinical situations [5,24]. 
To determine whether the acquisition of the MDR pheno- 
type by JD 100 cells had affected the functional properties of the 
scavenger receptors on JD100 cells, we compared the ability of 
J774A.1 and JD100 cells to bind and degrade [125I]MBSA 
DNM.  In the absence of any competing compound, approxi- 
mately 300 ng of MBSA-DNM per mg of cellular protein 
bound to both the cell types when incubated in presence of 6 
/.tg/ml of [125I]MBSA-DNM at 4°C for 2 h (Fig. la). The bind- 
ing of MBSA-DNM by both the cell types was inhibited 
Table 2 
Reversal of resistance to different drugs in JD100 cells by verapamil 
Drugs % of [SH]thymidine incorporation 
- Verapamil + Verapamil 
No addition 100 84 
0.05 /.tM Daunomycin 102 36 
0.025 /~M Doxorubicin 98 46 
0.007 /.tM Vincristine 76 8.7 
0.3 ¢tM Mitomycin C 8l 49 
0.5 ,uM Methotrexate 95 87 
0.77 pM 5-Flurouracil 101 80 
Cytotoxic activity of the indicated rugs was determined by measuring 
the amount of [3H]thymidine incorporated in the presence and absence 
of verapamil (20 pM) as described under Table 1. The drugs were used 
at ICs0 values for the parental J774A. 1 cells as in Table 1. [SH]thymidine 
incorporation by untreated control cells was taken as 100% and the 
results are expressed as the average of three independent experiments. 
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Fi~. 1. Binding and degradation f['25I]MBSA-DNM by JD100 and J774A. 1 cells. (a) Binding of [t25I]MBSA-DNM (6 #g/ml) in absence or presence 
of MBSA (300 #g/ml), polyguanylic acid (300 ltg/ml) and DNM (5 ,ug/ml) to the cells at 4°C was carried out as described insection 2. Results are 
expressed as ng of [t25I]MBSA-DNM bound per mg of cellular protein. (b) Degradation of [125I]MBSA DNM (6 flg/ml) alone or in the presence 
of :he competing compounds as above was carried out as described insection 2. Results are expressed asng of ['25I]MBSA-DNM degraded per mg 
of cellular protein. All values are corrected for the small amount of TCA-soluble "-5I radioactivity hat was present in the medium incubated with 
in I]MBSA DNM in the absence of cells, and represent average of triplicate incubations +S.D. 
(>80%) in presence of known ligands of the scavenger 
re,:eptor, viz., MBSA and polyguanylic acid, but not by free 
DNM indicating that the recognition of the drug-conjugate by
both the cell lines was mediated through the scavenger receptor. 
In both the cell types, binding of the drug conjugate was fol- 
lowed by its rapid internalization a d subsequent degradation. 
V~ hen incubated with 6 #g/ml of[125I]MBSA-DNM at 37°C for 
5 a, J774A.1, and JD100 cells degraded approximately 6365 
arid 5071 ng of MBSA-DNM per mg of cellular protein, respec- 
tively; the degradation of MBSA-DNM was competed by 
M BSA and polyguanylic acid but not by free DNM in both the 
cel types (Fig. lb). These data indicate that the drug resistant 
JD100 cells possessed functionally active scavenger receptors 
capable of efficient internalization of the drug conjugate at 
3" ~C which is followed by the proteolytic degradation of the 
M BSA moiety. 
1"o compare the cytotoxic efficacy of free and conjugated 
DXIM on the sensitive J774A.1 and resistant JD100 cells, we 
in,:ubated these cells in presence of the indicated concentrations 
ol free and conjugated DNM at 37°C for 1 h, and measured 
th,~ amount of [3H]thymidine incorporated by these cells in 
d] ag-free medium for 3 h (Fig. 2). The data presented in Fig. 
2~ shown the dose dependent inhibition of[3H]thymidine incor- 
p~ ration brought about by exposure of the drug sensitive 
J7 74A.1 cells to free DNM. There was 70% inhibition of 
[31 t]thymidine incorporation at0.3 #M DNM compared to the 
u] treated control, whereas free DNM under the same condi- 
ti, ns did not affect [3H]thymidine incorporation i the drug 
re,dstant JD100 cells. In contrast, treatment with conjugated 
DXlM (0.3 tiM) could inhibit [3H]thymidine incorporation i
dl ug resistant JD100 cells by 50% (Fig. 2b). 
Fig. 3 illustrates the effects of free and conjugated DNM on 
[3H]thymidine incorporation by JD100 cells as a function of 
time of exposure to the drug. When JDI00 cells were incubated 
with 0.3 #M DNM in the free form, the incorporation of 
[3H]thymidine by JDI00 cells was same as in untreated control 
cells over the experimental period of 240 minutes confirming 
the drug resistant phenotype expressed by the JD100 cells. In 
contrast, exposure of JD100 cells to DNM (0.3 tiM) in the 
conjugated form resulted in 50% inhibition of [3H]thymidine 
incorporation at 120 min. 
The data presented in Figs. 2 and 3 indicate that the DNM- 
resistance phenotype displayed by the multidrug resistant 
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Fig. 2. Cytotoxic activity of MBSA DNM and DNM on JV74A.I and 
JDI00 cells at 37°C. J774A.1 and JD100 were treated at the given 
concentrations of DNM in free (a) or conjugated form (b) for 1 h as 
described insection 2. Subsequently, the cells were washed thrice with 
1 ml of medium A, and in 1 ml of drug-free medium at 37°C. After 20 h, 
the cells were pulsed with 1 3 ml of [ H]thymidine (2#Ci/ml) containing 
medium A for 3 h at 37°C, and the amount of radioactivity associated 
with the cells were determined asin section 2. The results are expressed 
as percentage of [3H]thymidine incorporation by the untreated cells 
(average of three independent experiments _+ S.D.). 
















I I I I 
0 I I I i 
0 60 120  180 240 
TIME (Min) 
Fig. 3. Time course of killing of JD100 cells by MBSA-DNM or DNM 
at 37°C. Experiments were carried out as described under Materials 
and methods. JD 100 cells were incubated with 0.3/JM of DNM either 
in free or conjugated form for the indicated time periods, washed, and 
incubated indrug-free medium for 20 h. The cells were then pulsed with 
[3H]thymidine (2/JCi/ml) in drug-free medium for 3 h, washed and the 
radioactivity associated with the cells was determined. Cell-associated 
radioactivity in untreated control cells was taken as 100% and the 
results were expressed as an average of percentage incorporation of 
three independent experiments _+ S.D. 
JD100 cells could be largely overcome when the drug was 
presented as MBSA-DNM conjugate. In view of our previ- 
ously reported results showing many fold higher intracellular 
concentrations achieved when scavenger receptor bearing cells 
are presented with drugs conjugated with MBSA [13,25], it is 
likely that the DNM-resistant JD100 cells become susceptible 
to drug because an inhibitory intracellular concentration of
DNM could be achieved through scavenger receptor mediated 
uptake of MBSA-DNM. Alternatively, the receptor-mediated 
uptake of the drug conjugate may deliver the drug to an intra- 
cellular compartment which is not accessible to the Pgp-medi- 
ated efflux pump. It is also conceivable that the intralysosomal 
release of the drug through the receptor-mediated modality 
might provide a more effective access to the intracellular target 
of DNM action. Further studies are required to clarify the 
mechanism of the superior efficacy of MBSA DNM in circum- 
venting drug resistance. 
The idea of utilizing ligands of surface receptors as carriers 
of drugs, both to target them to specific cells and generate 
optimal intracellular concentration has been exploited earlier 
by our laboratory [13-15,25] and by others (reviewed in [12]). 
However, no attempts have yet been reported to apply the 
aforementioned approach to overcome the problem of MDR. 
Our studies thus demonstrate he general principle that the 
process of receptor-mediated endocytosis of drug conjugates 
could be a viable approach for killing drug resistant neoplastic 
cells if the receptor systems exclusive for such cells are known. 
The present investigation suggests that this approach could 
permit use of the same drug, albeit in the conjugated form, in 
contrast to the use of immunotoxins. The current strategies for 
circumventing MDR, viz., use of chemosensitizers, liposomes, 
immunotoxins, or antibodies have serious drawbacks while the 
current approach of receptor-mediated intracellular delivery of 
anticancer drugs for overcoming multidrug resistance shows 
promise requiring further studies. 
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